BACKGROUND: Depression and anxiety are comorbidities of inflammatory bowel disease (IBD), and it is now recommended to screen IBD patients for these conditions. We screened patients using a novel computerized adaptive testing technology and compared the screening results to measures of disease activity. METHODS: Consecutive patients at our tertiary IBD clinic were asked to complete the validated CAT-MH™ survey (Adaptive Testing Technologies, Chicago, IL); we then reviewed disease and patient characteristics. Clinical remission status was determined based on clinical, laboratory, endoscopy and imaging results. Statistical methods included Fisher's exact test and Pearson Chi-square tests to assess association. Univariable and multivariable analyses were performed. RESULTS: We included 134 patients, of which 34 (25.3%) screened positive for depression and 18 (13.4%) screened positive for anxiety. We identified 19 (55.9 %) and 10 (55.5%) patients who were previously undiagnosed for depression and anxiety, respectively. Patients in clinical remission were less likely to screen positive for depression (OR 0.19; 95%CI 0.07-0.50) and for anxiety (OR 0.30; 95%CI 0.10-0.91). Compared to patients with negative CRP values, patients with positive CRP were more likely to also screen positive for depression (p=0.025) and anxiety (p=0.15). CONCLUSIONS: We demonstrate the utility of a novel testing technology for screening patients with IBD for depression and anxiety. We found a large number of patients with previously undiagnosed anxiety or depression and a significant positive association between clinically active IBD and these mental health conditions. This work supports and informs recommendations for mental health screening in the IBD population.
BACKGROUND: Depression and anxiety are comorbidities of inflammatory bowel disease (IBD), and it is now recommended to screen IBD patients for these conditions. We screened patients using a novel computerized adaptive testing technology and compared the screening results to measures of disease activity. METHODS: Consecutive patients at our tertiary IBD clinic were asked to complete the validated CAT-MH™ survey (Adaptive Testing Technologies, Chicago, IL); we then reviewed disease and patient characteristics. Clinical remission status was determined based on clinical, laboratory, endoscopy and imaging results. Statistical methods included Fisher's exact test and Pearson Chi-square tests to assess association. Univariable and multivariable analyses were performed. RESULTS: We included 134 patients, of which 34 (25.3%) screened positive for depression and 18 (13.4%) screened positive for anxiety. We identified 19 (55.9 %) and 10 (55.5%) patients who were previously undiagnosed for depression and anxiety, respectively. Patients in clinical remission were less likely to screen positive for depression (OR 0.19; 95%CI 0.07-0.50) and for anxiety (OR 0.30; 95%CI 0.10-0.91). Compared to patients with negative CRP values, patients with positive CRP were more likely to also screen positive for depression (p=0.025) and anxiety (p=0.15). CONCLUSIONS: We demonstrate the utility of a novel testing technology for screening patients with IBD for depression and anxiety. We found a large number of patients with previously undiagnosed anxiety or depression and a significant positive association between clinically active IBD and these mental health conditions. This work supports and informs recommendations for mental health screening in the IBD population.
Entities:
Keywords:
anxiety; comorbidities; depression; inflammatory bowel disease; mental health
Authors: M Anthony Sofia; Matthew A Ciorba; Katherine Meckel; Chai K Lim; Gilles J Guillemin; Christopher R Weber; Marc Bissonnette; Joel R Pekow Journal: Inflamm Bowel Dis Date: 2018-06-08 Impact factor: 5.325
Authors: David T Rubin; Ashwin N Ananthakrishnan; Corey A Siegel; Bryan G Sauer; Millie D Long Journal: Am J Gastroenterol Date: 2019-03 Impact factor: 10.864
Authors: Ashwin N Ananthakrishnan; Vivian S Gainer; Tianxi Cai; Raul Guzman Perez; Su-Chun Cheng; Guergana Savova; Pei Chen; Peter Szolovits; Zongqi Xia; Philip L De Jager; Stanley Shaw; Susanne Churchill; Elizabeth W Karlson; Isaac Kohane; Roy H Perlis; Robert M Plenge; Shawn N Murphy; Katherine P Liao Journal: Am J Gastroenterol Date: 2013-01-22 Impact factor: 10.864
Authors: J Jo Kim; Richard K Silver; Rita Elue; Marci G Adams; Laura M La Porte; Li Cai; Jong Bae Kim; Robert D Gibbons Journal: Arch Womens Ment Health Date: 2016-05-17 Impact factor: 3.633
Authors: James C Mundt; John H Greist; James W Jefferson; Michael Federico; J John Mann; Kelly Posner Journal: J Clin Psychiatry Date: 2013-09 Impact factor: 4.384
Authors: Robert D Gibbons; David J Weiss; Paul A Pilkonis; Ellen Frank; Tara Moore; Jong Bae Kim; David J Kupfer Journal: Arch Gen Psychiatry Date: 2012-11
Authors: Clarence K Zhang; Jennifer Hewett; Jason Hemming; Taneisha Grant; Hongyu Zhao; Clara Abraham; Ioannis Oikonomou; Meera Kanakia; Judy H Cho; Deborah D Proctor Journal: Inflamm Bowel Dis Date: 2013-07 Impact factor: 5.325
Authors: Robert D Gibbons; Giles Hooker; Matthew D Finkelman; David J Weiss; Paul A Pilkonis; Ellen Frank; Tara Moore; David J Kupfer Journal: J Clin Psychiatry Date: 2013-07 Impact factor: 4.384